mathematics - Page 3
Stories from mathematics come first, newest first, then stories from connected topics (Lean, AI Science & Health, research, AI for science, AI, OpenAI), each labelled with where it comes from. This view is not indexed by search engines.
Latest
IARC Launches INTERVENER Tool for Cancer Screening Barriers
IARC launched INTERVENER, a web tool matching cancer-screening barriers to evidence-based interventions. It is a planning tool, in English for now.
Bispecific Nanobody Neutralises Three Coronaviruses in Mice
A Georgia State-led bispecific nanobody neutralised all tested SARS-CoV, SARS-CoV-2 and MERS-CoV strains and protected mice. No human trials yet.
Boltz Raises $110 Million Series A for Molecular Design Tools
Boltz has raised a $110 million Series A led by Bessemer. The MIT-origin firm claims partnerships with six of the world's 20 largest pharma companies.
Groupe Figaro and OpenAI Partner to Put Le Figaro in ChatGPT
Groupe Figaro and OpenAI have partnered to make Le Figaro journalism discoverable in ChatGPT as summaries and excerpts. No terms or start date were given.
FDA Clears Sine Health App to Monitor Essential Tremor
The FDA has cleared Sine Health’s smartphone app as a monitoring aid for essential tremor, not a diagnosis or treatment. The “first” claim is Sine’s.
Maryland’s RoboScout Wins DARPA’s $1.5 Million Triage Prize
UMD's RoboScout team won DARPA's $1.5 million triage prize at a Texas training site, using drones and robot dogs in simulated mass-casualty drills.
OpenAI Launches GPT-6.2 Astra and Sol, Now on Bedrock
OpenAI has launched GPT-6.2 Astra and GPT-6.2 Sol in ChatGPT and the API, with same-day general availability on Amazon Bedrock.
Oregon AG Files $2.035 Billion Action Against OpenAI
Oregon has filed a $2.035 billion OpenAI action over ChatGPT and child safety. The claims are the state’s; no official OpenAI statement has been seen.
Isomorphic Labs Announces a $5 Billion Series C Funding Round
Isomorphic Labs has raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital. The company did not state a valuation.
Salk’s Superb-seq Reads CRISPR On- and Off-Target Edits
Salk scientists have published Superb-seq, which reads CRISPR on- and off-target edits in individual cells. It is a lab method, not a therapy.
Latest on TSN
Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.
